Brind.

Bristol-Myers Squibb's price target was cut by Cantor Fitzgerald following clinical setbacks.

4 reports, 2 independent Updated Oct 6
Gone quiet
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Bristol-Myers Squibb's price target was cut by Cantor Fitzgerald following clinical setbacks.

Who's involved

What this event is mainly about
Bristol-Myers SquibbCantor Fitzgerald

How it developed

Newest first. Tap a step to see who reported it.
  1. Bristol-Myers Squibb rating cut and restatements announced.1 source
  2. Cantor Fitzgerald cut BMS price target due to clinical setbacks.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • themarketsdaily.com
  • Insider MonkeyCantor Fitzgerald Cuts Bristol-Myers (BMY) Price Target, Keeps Neutral Bristol-Myers Squibb Company (NYSE:BMY) is one of the 10 Best Affordable Stocks Under $50 to Buy. On August 13, Cantor Fitzgeral
2 more outlets ran the same wire story